文献速递血脂与心血管预防心力衰竭与心肌病心律失常

基于蛋白质组学方法预测不同心血管疾病与痴呆

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia.
PubMed 文献 · Circulation · 2024-11-14

在UK Biobank 51 859名无心血管病且接受蛋白质组学检测的参与者中,评估血浆蛋白质组学方法对主要不良心血管事件(MACE)及多种次要结局的预测价值。中位随访13.6年期间4 857人发生首次MACE;蛋白质模型在验证队列中较PREVENT风险评分改善净重分类与C统计量。

要点

  • 蛋白质模型较PREVENT风险评分改善MACE的净重分类(NRI +0.09)与C统计量(+0.051)。
  • 蛋白质模型还改善ASCVD、心梗、卒中、主动脉瓣狭窄、心衰、腹主动脉瘤及痴呆的预测。
  • 与MACE关联最强的蛋白质包括NT-proBNP、proADM、GDF-15、WFDC2和IGFBP4。

核心结论

  • 靶向蛋白质生物标志物检测对聚合和分解的心血管事件产生更优的预测。
  • 本研究为靶向蛋白质组学预测一系列心血管结局提供了概念验证。

研究设计与样本

  • 在51 859名无心血管病且具有蛋白质组学测量的UK Biobank参与者中(平均年龄56.7岁,45.5%男性)开展研究。
  • 主要复合结局为致死性和非致死性冠心病、卒中或心力衰竭(MACE),并分析其他次要心血管结局。
  • 采用暴露组全关联研究,使用相对蛋白质浓度并调整经典、人口学和生活方式危险因素。
  • 蛋白质模型仅使用年龄、性别和蛋白质标志物,采用LASSO正则化方法开发(推导集:队列80%),并用拆分样本验证(队列20%)。
  • 通过比较校准、净重分类指数和C统计量与PREVENT风险评分评估性能。

主要发现

  • 中位随访13.6年期间,4 857名参与者发生首次MACE。
  • 调整后与MACE关联最强的蛋白质包括NT-proBNP(每SD升高HR 1.68)、proADM(HR 1.60)、GDF-15(HR 1.47)、WFDC2(HR 1.46)和IGFBP4(HR 1.41)。
  • 蛋白质模型中总计222种独立蛋白质是所有感兴趣结局的预测因子,其中86种被选用于主要结局。
  • 在验证队列中,与PREVENT风险因素模型相比,蛋白质模型改善MACE的净重分类(NRI +0.09)和C统计量(+0.051)。
  • 蛋白质模型还改善其他结局的预测,包括ASCVD(C统计量+0.035)、心肌梗死(+0.023)、卒中(+0.024)、主动脉瓣狭窄(+0.015)、心力衰竭(+0.060)、腹主动脉瘤(+0.024)和痴呆(+0.068)。

临床怎么用

  • 靶向蛋白质组学检测可辅助改善多种心血管疾病和痴呆的风险预测。
  • 在经典危险因素基础上,蛋白质模型可改善MACE及其他心血管结局的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many studies have explored whether individual plasma protein biomarkers improve cardiovascular disease risk prediction. We sought to investigate the use of a plasma proteomics-based approach in predicting different cardiovascular outcomes. METHODS: Among 51 859 UK Biobank participants (mean age, 56.7 years; 45.5% male) without cardiovascular disease and with proteomics measurements, we examined the primary composite outcome of fatal and nonfatal coronary heart disease, stroke, or heart failure (major adverse cardiovascular events), as well as additional secondary cardiovascular outcomes. An exposome-wide association study was conducted using relative protein concentrations, adjusted for a range of classic, demographic, and lifestyle risk factors. A prediction model using only age, sex, and protein markers (protein model) was developed using a least absolute shrinkage and selection operator-regularized approach (derivation: 80% of cohort) and validated using split-sample testing (20% of cohort). Their performance was assessed by comparing calibration, net reclassification index, and c statistic with the PREVENT (Predicting Risk of CVD Events) risk score. RESULTS: Over a median 13.6 years of follow-up, 4857 participants experienced first major adverse cardiovascular events. After adjustment, the proteins most strongly associated with major adverse cardiovascular events included NT-proBNP (N-terminal pro B-type natriuretic peptide; hazard ratio [HR], 1.68 per SD increase), proADM (pro-adrenomedullin; HR, 1.60), GDF-15 (growth differentiation factor-15; HR, 1.47), WFDC2 (WAP four-disulfide core domain protein 2; HR, 1.46), and IGFBP4 (insulin-like growth factor-binding protein 4; HR, 1.41). In total, 222 separate proteins were predictors of all outcomes of interest in the protein model, and 86 were selected for the primary outcome specifically. In the validation cohort, compared with the PREVENT risk factor model, the protein model improved net reclassification (net reclassification index +0.09), and c statistic (+0.051) for major adverse cardiovascular events. The protein model also improved the prediction of other outcomes, including ASCVD (c statistic +0.035), myocardial infarction (+0.023), stroke (+0.024), aortic stenosis (+0.015), heart failure (+0.060), abdominal aortic aneurysm (+0.024), and dementia (+0.068). CONCLUSIONS: Measurement of targeted protein biomarkers produced superior prediction of aggregated and disaggregated cardiovascular events. This study represents proof of concept for the application of targeted proteomics in predicting a range of cardiovascular outcomes.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Ho FK, Mark PB, Lees JS, et al. A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia. Circulation. 2024. PMID: 39540306. doi:10.1161/CIRCULATIONAHA.124.070454

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。